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Abstract
Background: There is a paucity of information about the molecular perturbations involved in MPM tumor
formation. We previously reported that EGFR-TK mutations in MPM were predictive of achieving optimal surgical
cytoreduction, but the status of EGFR pathway activation potential of these mutations was not known. Here we
present the mutant EGFR activating potential and the matured survival data of the EGFR mutant(mut+) relative to
wild type EGFR(mut-) mesothelioma.
Methods: Twenty-nine patients were evaluated and their tumors were probed for mutations in the catalytic TK-
domain. Twenty-five patients were treated with cytoreductive surgery and complete clinical data was available for
comparison of the mut+ and mut- groups. A COS-7 cell expression model was used to determine mutation
activating profiles and response to erlotinib.
Results: Functional mutations were found in 31%(9/29) of patients; 7 of these mutations were novel and another
was the L858R mutation. All missense mutations were found to be activating mutations and responsive to
erlotinib. Of the 25 patients managed surgically, there were 7 mut+ and 18 mut-. Two of 7 (29%) mut+ developed
progressive disease and died with a median follow-up time of 22 months; while 13/18 (72%) mut- developed
progressive disease and 10/18 (56%) died with median TTP of 12 months and median survival of 14 months.
Conclusions: The novel EGFR mutations identified are activating mutations responsive to erlotinib. The mut+
subset have a ‘relative’ improved outcome. Erlotinib may have a role in MPM and exploration for mutations in a
larger patient cohort is warranted.
Introduction
Discovering the molecular pathways and mutations
active in cancer has resulted in the emergence of novel
therapies, as well as, the development of objective pre-
dictors of clinical outcome and response to cancer
therapies. Perturbations and mutations in the epidermal
growth factor receptor gene family have been identified
in many cancer subtypes with gain of function altera-
tions occurring at all levels of gene and protein expres-
sion [1-4]. Recent studies in non small cell lung cancer
(NSCLC) have revealed that mutations in epidermal
growth factor receptor (EGFR) occur in 15% of Cauca-
sians and 30% of Asians with NSCLC, and the presence
of specific EGFR mutations is predictive of response to
therapy and cancer outcome [5-8]. The reported muta-
tions in NSCLC are deletion or missense mutations that
occur between exons 18-24 in the tyrosine kinase
domain of the receptor. Investigation of EGFR muta-
tions in lung cancers has become a pivotal research
paradigm that has begun to unlock the utility of muta-
tions in predicting clinical outcomes, selection of
patients for therapies (EGFR-TKIs), and predicting
response/resistance to these therapies.
Recapitulation of EGFR mutations in lung cancer cells
in vitro have demonstrated that it is an example of an
‘oncogenic addiction’ mutation which provides a biolo-
gic explanation for the improved outcome seen in this
EGFR mutant NSCLC group relative to the wild type
group [9]. EGFR mutations are likely not limited to lung
cancer and pervasive in other cancer. A potential cancer
type similar to NSCLC that might harbor functional
EGFR mutations is malignant mesothelioma. The first
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expression is quite common in malignant mesothelioma
[10-12]. Also malignant mesothelioma, like NSCLC, is a
highly lethal cancer that can arise de novo in the pleural
cavity; but unlike NSCLC, mesothelioma can also origi-
nate in the peritoneal cavity and soft tissue. Malignant
peritoneal mesothelioma (MPM), like pleural mesothe-
lioma, is quite aggressive, with most patients succumb-
ing to this disease within 7-14 months after diagnosis
[13]. Treatment of MPM with systemic chemotherapy,
radiation, and/or palliative surgery has largely been
unsuccessful in improving outcome or extending survi-
val. However, over the last two decades, many groups
have shown that aggressive surgical cytoreduction con-
solidated with intraperitoneal hyperthermic chemother-
apy (CRS/IPHC) can improve improved patient outcome
in a subset of patients. CRS/IPHC has been the only
treatment modality that has yielded long-term survival
and cure in selected patients [10,14-19]. At our institu-
t i o n ,w ep e r f o r mah i g hv o l u m eo fC R S / I P H Cf o ra l l
forms of peritoneal surface malignancies. Through this
experience it is evident that many mesothelioma
patients do not experience the long term benefits of this
aggressive surgical intervention, but all must endure the
associated morbidity and mortality. Therefore, identifica-
tion of surrogate markers that can predict response to
CRS/IPHC and lead to novel therapeutic targets in
mesothelioma prompted the pursuit of EGFR mutations.
We have previously reported that EGFR mutations
occur in 31% of MPM, a rate similar to that reported in
NSCLC [20]. When mutations were present they corre-
lated with optimal surgical resection in 100% of the
patients. Since most patients who present with MPM
are unresectable, achieving optimal resection is impor-
tant because it represents the only reproducible (surro-
gate) factor that predicts long-term survival [14]. Here
we report the first identification of EGFR activating
mutations in mesothelioma, as well as, the updated clin-
ical outcome.
Materials and methods
Patient population
Twenty-nine consecutive cases of newly diagnosed
malignant peritoneal mesothelioma evaluated at
Creighton University Medical Center from January 1,
2003 to July 31, 2006 were reviewed. All cases had par-
affin embedded tissue available to perform immunos-
taining and mutation analysis. Institutional review board
approval was obtained for this investigation.
Mutation analysis of EGFR in malignant mesothelioma
Tumor tissues were procured from patients who had
undergone surgical resection at the department of sur-
gery, Creighton University Medical Center, Omaha,
from January 2003 to July 2006. Twenty-nine formalin-
fixed paraffin-embedded tissues were available for the
analysis. All patients had pathologically proven MPM.
The study was approved by the institutional review
board of the Creighton University Medical Center. Med-
ical records and hematoxylin and eosin-stained slides of
the specimen were reviewed by two pathologists. Tumor
tissue with a tumor cell content of greater than 30-40%
was chosen for the analysis. In several cases, tissue sec-
tions were microdissected manually to obtain both
tumor and histologically normal tissue.
Genomic DNA was isolated from tumors embedded in
paraffin blocks using Puregene DNA Purification kits
(Gentra systems® MN, USA) according to manufacturer’s
protocol. The EGFR gene (Epidermal growth factor
receptor, EGFR; MIM 131550), (Ensembl Gene ID
ENSG00000146648) has a total of 28 exons. Genomic
DNA were PCR-amplified for 7 different genomic
regions of EGFR (Exon 18-24) covering the entire coding
sequence of the tyrosine kinase domain and all asso-
ciated splice junctions. Amplified PCR products were
first screened by DHPLC heteroduplex analysis using
the Transgenomic WAVE® system (Transgenomic,
Omaha, NE) as previously described. Samples with var-
iant DHPLC profiles were purified with QIAquick spin
columns and sequenced directly (BigDye® Terminators
sequencing kit, Foster City, CA) in both directions using
an automated ABI 3100 genetic analysis system and ana-
lyzed using the Sequencer 4.1 software program package
(Gene Codes®, Ann Arbor, MI). Mutant alleles were also
cloned by use of the original TA cloning kit (Invitrogen
Carlsbad, CA) according to manufacturer’sp r o t o c o l ,
after PCR amplification, purified and subjected to
nucleotide sequencing.
Functional Analyses of Mutant EGFRs
Full length wild-type EGFR cDNA (Gene bank accession
No. NM_005228) were cloned into pIRES-hrGFP-2a
expression vector (Stratagene® La Jolla, CA). Mutations
(W731L, E734Q, T785A, C797Y, Y801H, L831H, L858R
and E868G) were introduced into full-length EGFR coding
sequence by using a QuikChange II XL Site-Directed
Mutagenesis kit (Stratagene). All mutant clones were
sequenced to ensure that no additional mutations
were introduced. The COS-7 cell line was obtained from
American Type Culture Collection (ATCC® Manassas,
VA) and grown in DMEM with high glucose, 10% FCS, 2
mM L-glutamine (GIBCO® Carlsbad, CA), 10 units/ml
penicillin, and 10 μg/ml streptomycin. Cells were trans-
fected (Lipofectamine LXT, Invitrogen) using one tube
protocol. Briefly, 12.5 μg of the expression constructs were
mixed thoroughly with 2.5 ml of Opti-MEM I reduced
serum medium (Invitrogen) and incubated for 30 minutes
at room temperature. DNA-Lipofectamine complexes
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medium then plated equal volume in five p60 tissue cul-
ture dishes (Falcon® San Jose, CA) and incubated at 37°C
and 5% CO2. Six hours after the transfection, 2 ml of
DMEM with high glucose, 20% FCS was added to each
dish. The next day, cells were switched to reduced serum
medium and incubated overnight with 10 ng of EGF per
milliliter (Sigma® St. Louis, MO). To evaluate the in vitro
responsiveness of mutant receptors to EGFR inhibitor,
cells were treated with various concentrations of Erlotinib
(Tarceva® LC laboratories, Woburn, MA) three hours
before the addition of 10 ng of EGF per milliliter. The
Stock solutions of Erlotinib were prepared in DMSO and
prior to use, diluted in fresh DMEM media. Three inde-
pendent experiments were performed for all analyses.
Cells were exposed to EGF for 15 minutes. The protein
preparation and Western blot analysis was performed fol-
lowing the methods described previously.
Equal amounts of protein were prepared in 50 μlo f
Laemmli loading buffer andr e s o l v e du s i n g4 - 1 5 %
Figure 1 Identification of missense mutations in MPM tumor samples. Chromatograms of MPM (Panels A1-A8) and normal (Panels B1-B8)
samples.
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Rad® Hercules, CA), transferred to nitrocellulose mem-
branes. The efficiency of transfer and uniformity of
loading were determined by Ponceau S (Sigma) stain-
ing. Western blot analysis was performed with the use
of either super signal West femto maximum sensitivity
substrate and/or West pico chemiluminescent sub-
strate reagents (Thermo scientific® Rockford, IL).
Nitrocellulose membranes were incubated overnight
a n dp r o b e dw i t ha n t i - p h o s p h o - EGFR (Cell Signaling
Technology®, Danvers, MA), and EGFR antibody (Cell
Signaling Technology). The densities of specific protein
Figure 2 Schematic representation of EGFR protein with the intracellular, transmembrane, extracellular and the TK domains.T h e
known phosphorylation sites (residues numbered) are marked on the left side. Mutations found in MPM samples are marked on the right.
Numbers within bars are exons.
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GS-800 Imaging Densitometer, Bio-Rad®).
Survival and time to progression analysis
The statistical analyses were performed in an explora-
tory manner on twenty-five patients who underwent
surgical exploration for cytoreductive surgery and intra-
peritoneal hyperthermic chemotherapy. When IPHC
was performed, patients received either 30-40 mg of
Mitomycin C or 800 mg/M2 of Carboplatin at an inflow
temperature of 40.5-42°C for 90-120 minutes. The level
of cytoreduction was scored as R1 – no visible disease,
R2a – residual tumor nodules ≤ 5m m ,R 2 b– residual
tumor nodules > 5 mm ≤ 2c m ,R 2 c>2c m ,a n dR 3 -
unresectable. Optimal resectability was defined as an R1
or R2a resection. To determine the impact of the pre-
sence of mutation on survival and time to progression, a
log rank analysis was performed.
Results
Mutation analysis
We analyzed a cohort of MPM samples (n = 29) by
DHPLC and sequencing analysis, and identified eight
mutations in the tyrosine kinase domain (TKD) of
EGFR. Of the 8 mutations in the TK domain, 7 were
novel (W731L, E734Q, T785A, C797Y, Y801H, L831H
and E868G) (Figure 1A, B). One of the mutations
(L858R) was previously identified in non-small cell lung
cancer (NSCLC) patients and this mutation was found
to increase sensitivity to EGFR inhibitor, Erlotinib. All
mutations were determined to be somatic, since they
were not identified in the analysis of normal tissue from
the same patients. Each mutation was only observed
once in this cohort, except L831H which was detected
in two independent tumors. In addition, analysis of 100
unrelated normal controls from the same ethnic origin
did not identify these variants indicating that these are
most likely not rare polymorphisms. No mutations were
identified within the kinase domain of ERBB2 in this
MPM sample set.
EGFR and ERBB2 copy number status was assessed
using FISH and quantitative PCR, and no evidence of
amplification of either gene was found in all specimens
(data not shown). Expression of the EGFR alternative
transcript variant, EGFRvIII, could not be detected by
RT-PCR (data not shown).
All the mutations were in the TK domain that is criti-
cal for EGFR activity (Figure 2). Sequence alignment of
the human wild- type EGFR with the Pfam model of
protein kinase domain indicates W731, E734, T785,
C797, Y801, R831, L858 and E868 that the mutations
were in highly conserved residues (Figure 3).
Time-response studies of EGFR on MM mutations in COS
7 cells
The functional properties of the EGFR mutations were
tested by transient transfection assays. The eight muta-
tions were first introduced into the wild type human
EGFR by site directed mutagenesis. The mutant EGFRs
were then transfected into COS-7 cells and exposed to
EGF. Total proteins isolated from these cells were
resolved by SDS-PAGE, blotted and probed with anti-
phospho EGFR (Y1068) and anti-EGFR antibodies.
EGFR activation was assayed by quantification of tyro-
sine 1068 (Y1068) residue, commonly used as a marker
of autophosphorylation of EGFR . All mutant EGFRs
showed enhanced phosphorylation in a time-dependent
manner, with a maximal response at 15 minutes. All
the 8 mutations showed a similar activation profile
(Figure 4, 5). These results demonstrated that the
mutations were activating.
Dose response studies of Erlotinib on COS-7 transfected
cells
In order to investigate whether the EGFR mutations are
sensitive to the EGFR inhibitor Erlotinib, COS-7 cells
transfected with mutant EGFR and treated with various
concentrations (0.002 to 2.0 μM) of Erlotinib and
exposed to EGF. EGFR phosphorylation was significantly
decreased in a dose-dependent manner for all eight
Figure 3 Amino acid sequence comparisons of EGFR-TK domain from members of the EGFR family of proteins from different species.
The amino acids at position W731, E734, T785, C797, Y801, R831, L858 and E868 were conserved in several species.
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mal response at 2.0 mM (Figure 6, 7).
Impact of EGFR mutations on survival and time to
progression (TTP)
Twenty-five of the 29 patients were treated with surgi-
cal cytoreduction and intraperitoneal hyperthermic
therapy with median follow-up time of 24 months.
Eight patients had tumors with mutant EGFR while
the other 17 patients had wild type EGFR. In the
EGFR mutant patients, median survival has not been
reached but 29% (2/7) of patients have died due to dis-
ease progression with a median follow-up time of 22
months; while 56% (10/18) of wild type patients have
Figure 4 EGFR mutations from MPM tumor samples are
activating mutations. Western blot analysis of phosphorylated
EGFR and total EGFR from transfectants expressing EGFR mutations.
Figure 5 Quantitative analysis of EGFR phosphorylation in
COS-7 cell transfectants expressing mutant EGFR.
Autoradiographs of three independent experiments were quantified.
The intensity of EGFR phosphorylation has been adjusted for total
EGFR expression. Error bars denote standard deviation.
Figure 6 EGFR mutations are sensitive to Erlotinib treatment.
Western blot analysis of COS-7 cell lines expressing MPM EGFR
mutants following treatment with Erlotinib. Inhibition of EGFR
phosphorylation and total EGFR levels were shown relative to
controls treated with Erlotinib.
Figure 7 Quantitative analysis of phosphorylation in COS-7 cell
transfectants expressing mutant EGFR following treatment
with Erlotinib. Autoradiographs of three independent experiments
were quantified. The intensity of EGFR phosphorylation has been
adjusted for total EGFR expression. Error bars denote standard
deviation.
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of 14 months. The time to progression in the wild type
group is 12 months with 72% (13/18) of patients devel-
oping progressive disease. However, only 29% (2/7) of
EGFR mutant patients have developed progressive dis-
ease and median TTP has not been reached. Log rank
analysis revealed that 3-year OS and DFS was 71% and
71% for the mutant group; 44% and 21% for the wild
type group (Figure 8A, B).
Discussion
We have identified seven novel and one known point
mutations in the EGFR-TK domain in MPM patients.
All mutations are clustered and reside near the ATP-
binding cleft of the tyrosine kinase domain. Presence of
each mutation in heterozygous condition indicates that
these mutant proteins with intact domains may influ-
ence wild-type protein expressed from the non-affected
allele and/or other EGFR factors in a dominant-negative
Figure 8 (A) Log rank analysis of death due to disease and (B) progression free survival based on the presence of a functional EGFR
mutation.
Foster et al. World Journal of Surgical Oncology 2010, 8:88
http://www.wjso.com/content/8/1/88
Page 7 of 10manner by the occupation of their binding sites through
mutant EGFR proteins. These mutation add to the list
of previously identified mutations within the kinase
domain of the EGFR gene, and also extends the spec-
trum of malignancies that harbor functional EGFR
mutations. To our knowledge, this is the first report
identifying functional EGFR mutations in malignant
mesothelioma.
Functional analyses of these mutant EGFRs in the cul-
tured cells demonstrated that all EGFR mutants have
enhanced tyrosine kinase activity in response to epider-
mal growth factor and increased sensitivity to EGFR
inhibitor Erlotinib. Like other mutants reported in the
literature, all eight EGFR mutants were ligand depen-
dent and in the absence of EGF stimulation there was
little or no activation of any mutant EGFR. These results
Figure 9 (A) Log rank analysis of death due to disease base on cytoreduction score (optimal vs. sub-optimal, previously published in
Annals Surg Oncology 2009 Jan: 16(1) 152-8); (B) Superimposed log rank analysis of death due to disease base on cytoreduction
score and PFS based on mutation.
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TKD mutant EGFR as being ligand dependent in similar
transient expression systems (NIH3T3 and HeLa cells),
while there was no evidence of significant ligand inde-
pendent EGFR activation.
Clinically, the presence of EGFR mutations in MPM
appears to predict response to therapy (CRS/IPHC) and
represents a potential predictor of improved outcome
compared to the wild type MPM. We have previously
reported that presence of EGFR mutation(s) in MPM is
predictive of optimal resectability, the only reproducible
surrogate marker for long term survival with this disease
[14]. While resectability is useful, it does not circumvent
the associated risks of CRS/IPHC and often cannot be
determined preoperatively given the miliary nature of
this disease. In figure 9A the optimal resected patients
have a statistically significant survival benefit relative to
sub-optimal group and a similar outcome was observed
in the mutant EGFR patients relative to wild type EGFR
group (Figure 9B). In the 13/18 wild type patients that
developed progressive disease 10 have died and 3 are
currently enrolled in hospice with comfort care
measures.
The impact of EGFR mutations in MPM strikingly
parallels the observation reported in NSCLC. Specifically
the finding that EGFR mutations are predictive of
response to therapy [5-8,21-25]. In lung cancer this has
been demonstrated in the context of systemic che-
motherapy and/or EGFR-TK therapy. In this study,
treatment is cytoreductive surgery with intraperitoneal
hyperthermic chemotherapy. The finding that EGFR
mutations identify responders to therapy mechanistically
is explained at the cellular/molecular by the ‘oncogenic
addition (shock)’ model [9,26-28]. In this model, cancers
that are dependent on critical oncogenic pathways, like
the EGFR pathway for tumor cellular maintenance,
undergo an exaggerated/prolonged apoptosis relative to
wild type tumor cells when exposed to the same cyto-
toxic agents [9]. The improved outcome in EGFR MPM
mutants is also supported by this model. First, all gross
disease is removed surgically, leaving only microscopic
to low volume residual disease. This residual disease
subsequently is treated with high dose intra-peritoneal
chemotherapy and hyperthermia given intra-operatively,
and the intrinsic susceptibility of EGFR MPM mutant
tumors makes these cells more likely to undergo more
extensive apoptosis which manifests as a prolonged pro-
gression free survival (Figure 9B).
Although the mutant EGFR group experienced a pro-
longed survival, two patients in this group have suc-
cumbed to their disease, and likely with longer follow-up,
more mutant EGFR patients will develop progressive
disease. Therefore, the improved outcome observed in
the mutant EGFR group is a ‘relative’ phenomenon.
This ‘relative’ outcome improvement in mutant MPM
patients also parallels the observations in metastatic
lung cancer which report prolonged median survival
but ultimately most patients, including EGFR mutants
succumb to progressive diseases. Since NSCLC clini-
cally are responsive to TKI therapy and given the in
vitro response of the MPM mutations to Erlotinib,
t h e r em a yb ear o l ef o rE G F R - T K It h e r a p yi nM P M
EGFR mutant patients who develop disease recurrence
or present with bulky unresectable tumor. Currently
EGFR-TKI therapy has not been investigated in perito-
neal mesothelioma but a recent trial in pleural
mesothelioma did not show any benefit [29]. Interest-
ingly in this erlotinib trial, the high EGFR expressing
tumor group experienced a 2-fold longer survival, but
study did not interrogate tumors for EGFR mutations.
Therefore it is unknown if EGFR mutations occur in
pleural mesothelioma or if a subset of mesothelioma
patients might benefit from EGFR-TKI therapy and
further investigation for perturbations in the EGFR
pathway in pleural mesothelioma is warranted.
In summary, we have identified novel activating EGFR
mutations in MPM associated with optimal resectability
and prolonged survival. Clinically these mutations may
ultimately have utility in patient selection for surgery,
systemic therapy, and selection for EGFR-TKI. The
identification of EGFR mutations in peritoneal mesothe-
lioma expands the spectrum of cancers with EGFR path-
way perturbations and provides the first evidence of
function EGFR mutations in mesothelioma. Not only
does the ‘in vitro’ biological behavior of these mutations
parallel those identified in NSCLC, but the clinical
course of MPM patients with EGFR mutant tumors
appear to share same ‘relative’ improved clinical out-
come like mutant EGFR-NSCLC. Expanding the cohort
of peritoneal mesothelioma and probing for mutations
in pleural based disease is warranted.
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